Nexavar (sorafenib tosylate) — United Healthcare

Initial criteria

• Chordoma: diagnosis of chordoma AND disease is recurrent
• OR Osteosarcoma / dedifferentiated chondrosarcoma / high‑grade undifferentiated pleomorphic sarcoma: diagnosis of one listed AND not used as first-line therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Nexavar therapy

Approval duration

12 months